Abstract:OBJECTIVE: Several epidemiological studies have indicated that the long‐term administration of non‐steroidal anti‐inflammatory drugs (NSAIDs) may reduce the incidence of colorectal cancer. The best known action of NSAIDs is to block cyclooxygenase, the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two cyclooxygenase isoforms have been identified and these are referred to as COX‐1 and COX‐2. Recent studies indicate that inducible COX‐2 plays an important role in gastrointestinal inflammation and carcinogenesis. The present study was undertaken to investigate the expression and clinical implications of COX‐2 and COX‐1 in normal and diseased colons. METHODS: COX‐2 and COX‐1 protein expression in specimens from normal controls and diseased colon tissues were examined semiquantitatively by using immunohistochemical methods. RESULTS: By using immunohistochemical detection methods, low COX‐2 protein expression in colonic epithelial cells was observed in 20.0% (2/10) of normal controls. Eighty percent (16/20) of specimens from inflammatory bowel disease (IBD) had a high COX‐2 expression, 46.40% (13/28) of adenomas and 64.3% of (9/14) well‐differentiated colonic carcinomas had some COX‐2 protein expression. Expression of COX‐2 protein was increased in IBD and colonic carcinomas compared with normal controls. There were no significant differences between colonic adenomas and colonic carcinomas. No correlation was found between COX‐2 protein expression and patient gender, patient age, tumor size, tumor location or the degree of differentiation/ metastasis of the tumor. Strong immunoreactive COX‐2 was expressed in clusters in interstitial cells (mainly mononuclear cells) in 53.6% (15/28) of adenomas and 64.3% (9/14) of colonic carcinomas. Strong COX‐2 protein expression was also displayed in the normal glands that were adjacent to the adenomas and carcinomas. Expression of COX‐1 protein was observed in the epithelial cells and interstitial cells or tumor cells of normal colon, IBD, colonic adenomas and colonic carcinomas. CONCLUSIONS: Our results indicated that COX‐2 protein overexpression may contribute to the development of IBD and colonic carcinogenesis.

Role of COX-2 and 15-PGDH expression in colorectal tumorigenesis

Expression of cyclooxygenase 2 in colorectal cancer

Expression and clinical significance of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in gastric cancer

Role of COX-2 in Carcinogenesis of Colorectal Cancer and Its Relationship with Tumor Biological Characteristics and Patients’ Prognosis

Relationship Between COX-2 Expression and Clinicopathological Features of Colorectal Cancers

Expression of 15-PGDH is Downregulated by COX-2 in Gastric Cancer.

Expression of Cyclooxygenase‐2 Protein in Colon Disease

[Expression of Tissue Microarray P53, P16 and Cyclooxygenase-2 in Gastric Cancer].

The Expression and Significance of COX-2 and VEGF in Colorectal Adenocarcinoma

Significance of COX-2 and Inos Expression in Colorectal Adenocarcinoma

Expression of P53, P16 and Cyclooxygenase-2 in Esophageal Cancer with Tissue Microarray

Expression of COX-1 and COX-2 in colorectal adenoma

COX-2 expression and tumor angiogenesis in colorectal cancer.

Cyclooxygenase-2 Expression Is Up-Regulated In Human Pancreatic Cancer

Expression of cox-2 in human colorectal carcinoma and its clinical significance

Effects of Cyclooxygenase-2 and Proliferating Cell Nuclear Antigen on the Onset and Development of Familial Adenomatous Polyposis

Expression of Cyclooxygenase-2 Protein in Human Gastric Cancer

Expression of the cyclooxygenase-2 gene and its clinical significance in non-small cell lung cancer

The Expressions and Clinical Significance of COX-2 and Nm23-H1 in Human Colon Cancer

Expression of nuclear factor-κB and cyclo-oxgenase-2 in colonic adenoma polyps and colon cancer tissues and its relationship with angiogenesis

Study on COX-2 Expression in Colonic Mucosa of Patients with Colorectal Adenoma